It would be useful to assess its efficacy and tolerability in patients with comorbid psychiatric disorders and those with the inattentive subtype of ADHD.
ADHD is the most common childhood neuro behavioral disorder, with the most recent National Survey of Children's Health suggest ing a prevalence of 9.5% among children in the USA [1] . It causes significant impairment in academic performance and social functioning in affected youth, with symptoms frequently persisting into adolescence and adulthood [2] . Stimulant medications represent firstline pharmaco therapy for ADHD, with 70% of children and adolescents responding to a single stimulant trial, and up to 80-90% responding if both stimulant classes are prescribed consecu tively [3] . The average effect size for stimulant treatment versus placebo is calculated to be 1.0, which represents one of the largest effect sizes in psychiatric treatment [2] .
Although stimulants are highly effective, they are also associated with common adverse effects such as appetite suppression, insomnia and irri tability. In addition, they carry a risk of mis use and diversion [4] . If patients do not respond part of rEVIEW Daughton, Corr, Liu & West Indications & usage CLONXR is FDAapproved for the treatment of ADHD as monotherapy or as adjunctive therapy to stimulant medications for chil dren and adolescents aged 6-17 years [7] . The two clinical trials which led to FDA approval assessed end point efficacy measures at 5 weeks, while total study duration was 8 weeks in length (allowing for tapering of medication during the last 3 weeks) ( Table 1 ). As such, maintenance efficacy has not been systematically evaluated, so patients who are continued on longerterm treatment should be reassessed frequently for effectiveness and tolerability.
Dosage & administration
CLONXR is available in tablets of 0.1 and 0.2 mg, and is not scored. In this formulation, CLON is combined with cellulose ethers in a stable matrix which allows the release of CLON over a 12h period [6] . The medication should be swallowed whole and never cut, crushed or chewed, any of which would eliminate its XR capability. Dosing should be initiated with one 0.1 mg tablet at bedtime, and the daily dosage should be adjusted in increments of 0.1 mg/day at weekly intervals until the desired efficacy is achieved or tolerability problems arise (not to exceed maximum dose of 0.4 mg/day) ( Table 2) . Doses should be taken twice a day, with either an equal or higher split dosage given at bedtime. It is not recommended to directly substitute Adapted from [6, 11] .
adequately to treatment with stimulant medica tions or cannot tolerate stimulant medications, the American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters recom mend treatment with a nonstimulant medication [2] . Currently, the most studied non stimulant medication for the treatment of ADHD is atomoxetine, which selectively blocks reuptake at noradrenergic neurons, with more than a dozen doubleblind, placebocontrolled trials demonstrating safety and efficacy in ADHD and a calculated medium effect size of 0.7 [3] .
a2 agonists have emerged as an alternate ADHD medication strategy, either as mono therapy or as an adjunct to stimulant medica tions. Notably, the a2 agonists are the only medications US FDAapproved as an adjunc tive therapy for the treatment of ADHD. While immediaterelease a2 agonists have been available for some time, adherence with shortacting versions of oral clonidine (CLON) and guanfacine has been limited by the need for multiple daily dosing. In 2009, guanfa cine extended release (XR) (Intuniv™, Shire Specialty Pharmaceuticals, Dublin, Ireland) was approved by the FDA for the treatment of ADHD in children 6-17 years of age [5] . In 2010, an oral, XR version of CLON (Kapvay™, Shionogi Pharma, GA, USA) was approved for the treatment of ADHD in children aged 6-17 years [6] . Both medications reduce the need for multiple daily dosing.
the XR oral form for other CLON products on a mgpermg basis, because of differing pharmaco kinetic profiles between the extended and immediaterelease versions. When discon tinuing the medication, the dose should be tapered in decrements of no more than 0.1 mg every 3-7 days.
Clinical pharmacology
CLON is a central acting a2 adrenergic ago nist. It stimulates all three subtypes of a2 receptors in the brain. CLON reduces sym pathetic outflow from the CNS and decreases peripheral resistance, renal vascular resistance, heart rate and blood pressure [7] . The exact mechanism of action of CLON in ADHD is unknown.
CLONXR has different pharmacokinetics than immediaterelease CLON. It is suggested that the C max is 50% lower for CLONXR and occurs approximately 5 h later, compared with immediaterelease CLON. The total systemic bioavailability of CLONXR is approximately 89% of that for immediaterelease CLON. The two formulations have similar elimination half lives of approximately 12-16 h. Although studies with CLONXR have not yet evaluated CLON excretion or the effects of renal impairment, the results are likely to be similar to immediate release CLON. For immediaterelease CLON, the halflife can be as long as 41 h in those per sons with severe renal impairment and 40-60% of the absorbed dose is excreted, unchanged in the urine. For both medications, food has no effect on plasma concentration, bioavailability or elimination halflife.
Clinical evidence

Immediate-release CLON
Results of early acute pharmacotherapy treat ment studies suggested that immediaterelease CLON may be used most effectively in ADHD as part of a combination of treatments, such as when added to stable stimulant treatment. In treatment recommendations from the AACAP, published prior to approval of the XR prepara tion, immediaterelease CLON was suggested for offlabel use, as an adjunct to enhance stim ulant treatment or to treat comorbid symptoms such as impulsivity, tics or insomnia [2] . A 1999 metaanalysis assessed 11 studies which enrolled patients with or without various comorbid con ditions and calculated an effect size of 0.58 for immediaterelease CLON [8] .
One wellcontrolled study on the use of immediaterelease CLON in 136 children aged 7-12 years with ADHD and comorbid Tourette's syndrome randomly assigned sub jects to take one of four treatments: immediate release CLON, immediaterelease methylpheni date, CLON plus methylphenidate, or placebo for 12-16 weeks. CLON dosages averaged 0.25 mg/day for the CLONalone group and 0.28 mg/day for the CLON plus methylphe nidate group. Methylphenidate dosages aver aged 25.7 mg/day for the methylphenidate alone group and 26.1 mg/day for the CLON plus methylphenidate group. Both medications were dosed two to threetimes daily. All active treatments were superior to placebo in improv ing ADHD as well as tic symptoms, while the combination treatment resulted in the great est benefit for both disorders. The investigators suggested that immediaterelease CLON was helpful for aggression, impulsivity and sleep problems [9] . Last, the active treatments were well tolerated, including absence of any evident cardiac toxicity or drug-drug interactions.
Another controlled study enrolled 122 chil dren aged 6-12 years with ADHD and no other comorbidities. Subjects also received one of four treatments: immediaterelease CLON, immediaterelease methylphenidate, CLON plus methyl phenidate, or placebo. In this study, CLON was dosed three to fourtimes daily. The mean daily doses of medication were 0.24 mg for the CLONalone group and 30.2 mg for the methyl phenidatealone group. rEVIEW Daughton 
For subjects receiving combination treatment, the mean daily doses were 0.23 mg for CLON and 25.4 mg for methyl phenidate. CLON alone, in this study, was not statistically different from placebo, however, the combination treatment provided a better response for reducing ADHD symptoms [10] .
CLON-XR
In September 2010, an XR preparation of CLON was approved for use in pediatric ADHD. This approval was based on two randomized, pla cebocontrolled studies (Table 1 ). The first study was a multicenter, randomized, doubleblind, placebocontrolled study of two fixed doses (0.2 or 0.4 mg/day, divided dosing) of CLONXR in subjects aged 6-17 years with ADHD. Patients were titrated to their fixed dose increasing by 0.1 mg/day each week. The primary efficacy measure was the change in total ADHD Rating ScaleIV (ADHDRSIV) score from baseline to week 5. A significant effect was observed as early as week 2 and was maintained throughout the study period. The effect sizes were 0.713 for the 0.2mg/day group and 0.766 for the 0.4mg/day group [6] . Somnolence was the most common treatmentemergent adverse event and occurred more frequently during the weeks of dose esca lation than during dose maintenance or dose tapering. In this study, the most common treat mentemergent adverse events leading to discon tinuation were from somnolence/sedation (0% in placebo, 4% in the 0.2mg/day group and 6% in the 0.4mg/day group) and fatigue (0% in placebo, 3% in the 0.2mg/day group and 5% in the 0.4mg/day group). In approximately 1% of the patients on 0.4 mg/day, formication, constipation, vomiting, prolonged QT interval or rash led to discontinuation [6] .
The second study was a multicenter, random ized, doubleblind, placebocontrolled trial of a flexible dose of CLONXR as adjunctive therapy to a psychostimulant in subjects aged 6-17 years with ADHD [11] . Patients with ADHD who had an inadequate response to their psychostimu lant, defined as a total score ≥26 on the ADHD RSIV questionnaire after a minimum of 4 weeks on a stable stimulant regimen (i.e., ≤10% varia tion in dose), were randomized to CLONXR or placebo in addition to their stimulant treatment for a total treatment period of 8 weeks. In the placebo plus stimulant group, 62% of patients were on a methylphenidate stimulant and 38% were on an amphetamine. In the CLONXR plus stimulant arm, 58% were administered a methylphenidate stimulant, and 42% were administered an amphetamine. CLONXR was initiated at 0.1 mg/day and titrated up to a maximum of 0.4 mg/day (divided dosing, twice daily) over a 3week period. Up until week 5, the dose of CLONXR could be adjusted to account for maximal efficacy and tolerability. After week 5 the dose was tapered, at a rate of 0.1 mg/week, until reaching the lowest possible dose (i.e., 0.1 mg/day) at week 8.
Of the CLONXR subjects, 76% were titrated up to the maximum dose of 0.4 mg/day. The primary outcome measure was the total change in ADHDRSIV score from baseline to week 5. The improvement in this score was statistically significant in the CLONXR plus stimulant group compared with the placebo plus stimulant group beginning in the first week of study treatment (week 2) and was maintained through week 8 [11] . No statistically significant effect versus placebo was observed between the CLONXR plus methylphenidate and the CLONXR plus amphetamine groups. By allow ing the stimulant medication regimen to vary on the basis of the response of individual patients (i.e., methylphenidate or amphetamine), it was impossible to determine whether specific combi nations of stimulant treatment with CLONXR were more effective than others. It is therefore unknown if the combination of CLON with one specific stimulant would be better than another, or what the effects of CLONXR would have been if a formal dose optimization phase had been used.
For all groups, the occurrence of treatment emergent adverse effects was higher during weeks 0-3 when the study drug was initiated and titrated compared with all other weeks, even in the placebo plus stimulant arm. In the placebo plus stimulant group, 3% discontinued treatment owing to increased heart rate (n = 1), aggression (n = 1) and somnolence (n = 1). In the CLONXR plus stimulant group, 1% dis continued owing to slowed thought processes (n = 1). More patients who received CLONXR plus stimulant reported somnolence/sedation and fatigue. Throughout the study, changes in cardiovascular parameters as a result of treat ment with CLONXR were consistent with known effects of the drug (i.e., decreased heart rate and blood pressure) but were not clinically significant. From baseline to week 5, patients in the placebo plus stimulant group had a mean increase in heart rate of 0.9 beats/min, a mean increase in systolic blood pressure of 0.4 mmHg, and a mean decrease in diastolic blood pressure of 0.1 mmHg. In the CLONXR plus stimulant group there was a mean decrease in heart rate of 4.7 beats/min, a mean decrease in systolic blood pressure of 3.5 mmHg, and a mean decrease in diastolic blood pressure of 0.7 mmHg. The cardiac parameters were similar between the subjects on CLON versus placebo during the discontinuation period.
Adverse reactions
The most common adverse reactions experi enced with CLONXR monotherapy include somnolence, fatigue and irritability (Table 3 ) [7] . The most common side effects experienced when combined with stimulant medication include somnolence, fatigue, headache, nasal conges tion and upper abdominal pain [11] . Somnolence and fatigue are generally worse during titration phases and occurred less than the immediate release form [12] . In one study, 14-21% of patients reported moderate somnolence with CLONXR compared with reports of moder atetosevere sedation/drowsiness in 42-55% of patients with immediaterelease CLON [12] . As an a2 adrenergic agonist, CLONXR has the potential to decrease blood pressure and heart rate. The study by Jain et al. demonstrated mean changes in systolic and diastolic measures of up to 8.8 mmHg and 7.3 mmHg, respec tively, and up to 7.7 beats/min in heart rate on the 0.4mg/day dose [6] . When combined with psychostimulant medication, effects are similar [11] . Alterations in electro cardiographic readings reflect the known pharmacology of CLON. In the study by Jain et al., the percent ages of patients with prolonged QTc interval (QTc ≥450) were 14% in the placebo group and CLONXR 0.4mg/day group and 11% in the 0.2mg/day group [6] . No patients had a QTc Adverse events with 5% or greater incidence in any active treatment group and at least twice the incidence of placebo. CLON: Clonidine; XR: Extended release. Data taken from [6, 11] .
rEVIEW Daughton, Corr, Liu & West reading ≥500 at any time during the study. As an adjunctive therapy to psychostimulant medi cations, no clinically significant change in QTc has been found [11] . CLONXR should be used with caution in patients with a history of hypotension, brady cardia, heart block, cardiovascular disease or who are at risk for syncope. Blood pressure and heart rate should be obtained at baseline, fol lowing any dose changes, and periodically while on stable treatment [7] . Clinicians should moni tor for any episodes of syncope or feeling faint after exertion, which may suggest an inadequate cardio vascular response to exercise challenge which may be induced by CLON.
Abrupt cessation of CLONXR has not been studied in children and adolescents. When tapering, the dose of CLONXR should be reduced in decrements of no more than 0.1 mg every 3-7 days. In hypertensive adults, abrupt discontinuation has resulted in symptoms of anxiety, brief lightheadedness, tightness in the chest, headache, flushing, nausea and tachy cardia. There are no known risks for abuse or dependence [7] .
Drug interactions
Drug interaction studies with CLONXR in children have not been conducted. However, reported interactions with oral immediate release formulations include the possibility of potentiated CNSdepressive effects with other sedating medications, and bradycardia and atrio ventricular block with agents that affect sinus node function or AV nodal conduction such as calcium channel blockers, bblockers and digitalis. Other possible interactions include potentiated antihypertensive effects with anti hypertensives and other CLONcontaining medications [7] .
Use in specific populations
Pregnancy CLONXR has a Category C pregnancy rating and is not recommended for use in pregnancy unless clearly needed [7] .
Nursing mothers
Caution is advised for nursing mothers as CLONXR is expressed in breast milk [7] .
Adults
CLONXR has not been studied in the treatment of ADHD in the adult population.
Preschool
CLONXR has not been studied in children with ADHD less than 6 years of age. Rat stud ies revealed no drug effects on fertility, sexual or neurobehavioral development in young rats exposed to approximately threetimes the maximum recommended dose [7] .
Renal impairment
The pharmacokinetic impact that renal impair ment has on CLON has not been studied in children. Patients with renal impairment should receive doses dependent on their level of impair ment with cautious titration and frequent monitoring of blood pressure and heart rate [7] .
Conclusion & future perspective
Although stimulants are effective and generally welltolerated in the treatment of ADHD, some patients clearly need nonstimulant alternatives. Based on the two recent studies discussed in this article, CLONXR is efficacious and relatively welltolerated on a shortterm basis for mono therapy or adjunctive therapy in the treatment of ADHD in children and adolescents. Long term followup is needed to help delineate the role of CLONXR in the longterm treatment of ADHD symptoms in children and adolescents. No writing assistance was utilized in the production of this manuscript.
